ホーム > 市場調査レポート > 医薬品

神経疾患

市場調査レポート

商品コード

1499967

多発性硬化症の世界市場の評価：MSタイプ別、薬剤クラス別、診断別、投与経路別、エンドユーザー別、地域別、機会、予測（2017年～2031年）

Multiple Sclerosis Market Assessment, By Type of MS, By Drug Class, By Diagnosis, By Route of Administration, By End-user, By Region, Opportunities and Forecast, 2017-2031F

出版日: 2024年06月25日
発行: Markets & Data
ページ情報: 英文 225 Pages
納期: 3～5営業日

カスタマイズ可能

全表示
概要
図表
目次

概要

サンプル依頼リストに入れる

世界の多発性硬化症の市場規模は、2023年の271億2,000万米ドルから2031年までに378億1,000万米ドルに達すると予測され、2024年～2031年の予測期間にCAGRで4.24%の成長が見込まれます。市場は、各国政府の取り組み、技術の進歩、免疫抑制剤需要の増加、再発寛解型疾患の治療、研究開発への注目の高まりなどのさまざまな要因によって形成されています。

世界中の政府は、多発性硬化症を管理するために使用される治療法について人々を指導および教育し、この疾患に対する人々の認識を促進するために、数多くの取り組みを行っています。これらの取り組みは、世界の多発性硬化症市場の拡大を加速し、地域の発展を支援するのに役立っています。AIベースのツールがますます使用されるようになり、世界の多発性硬化症市場を破壊しています。これらのツールは、新薬の開発に変化をもたらし、世界の多発性硬化症市場を一変させました。研究能力が向上し、多発性硬化症の治療に向けた先進の精密な医薬品の開発につながっています。

世界の多発性硬化症市場の成長は、さまざまなタイプの多発性硬化症を治療する免疫抑制剤に対する需要の高まりによって影響を受けています。これらの薬剤は免疫系の反応を変化させ、炎症を抑え、老化プロセスを遅らせる役割を担っています。世界の多発性硬化症市場は、再発寛解型多発性硬化症の治療薬に対する需要の増加によって牽引されています。さまざまな企業が、この疾患に関連する特定の困難や症状に対処することで需要を満たすためにカスタマイズされた治療法の開発に注力しています。世界の多発性硬化症市場の主要企業は、研究開発を通じて対症療法の改善に注力することで、疾患の進行を改善することを優先しています。こうした取り組みが、疾患管理に向けた革新的な技術開発を後押ししています。

例えば2024年5月、ウェイン州立大学医学部の分子医学・遺伝学センター教授兼副所長であり、小児科と神経学の教授でもあるAlexander Gow, Ph.D.は、多発性硬化症の可能性のある原因を突き止めるため、NMSS（National Multiple Sclerosis Society）から3年間64万4,827米ドルの研究助成を受けました。

市場成長を促進する政府の取り組み

近年、世界の多発性硬化症市場は、世界中の政府の積極的な関与により成長を示しています。政府は市場の発展を促進するために、この産業における研究開発を後押ししたり、多発性硬化症についての認識を広めたり、さまざまな教育プログラムを開催したりといった、複数の手段を積極的に講じています。このような取り組みを通じて、政府は多発性硬化症という疾患に対する認識を高め、革新的な治療を患者が受けられるようにするとともに、医療システムのインフラを改善したいと考えています。このような取り組みは市場成長を促進し、患者のアンメットニーズを満たすと同時に、よりよい疾病管理に向けた革新的なソリューションを促進する上で不可欠です。

例えば、著名な国の非営利団体であるMS Australiaは、2024年5月に政府が保健および医学の研究への資金提供を約束したことを称賛しましたが、神経学研究が十分な資金や注目を浴びていないことに懸念を表明しました。同団体は、多発性硬化症（MS）のような神経疾患は、医療研究の国家的な重要優先事項であるべきだと述べ、Neurological Research Missionの創設を求めました。

市場を促進する技術の進歩

AIの利用は、多発性硬化症のより先進かつ効率的な治療法の開発を促進し、世界の多発性硬化症市場の成長を促進する大きな要因となっています。これらの先進の器具は、すべての患者の要件を満たすカスタマイズされた治療計画を作成するのに役立つ疾患特異的な薬剤の開発を支援しています。AIは、多発性硬化症の診断に不可欠なMRIスキャンなどの放射線画像の解析に大いに役立ちます。

当レポートでは、世界の多発性硬化症市場について調査分析し、市場規模と予測、市場力学、主要企業の情勢と見通しなどを提供しています。

市場規模と予測
- 金額
- 数量
MSタイプ別
- 臨床的に孤立した症候群
- 再発寛解型多発性硬化症
- 二次進行型多発性硬化症
- 原発性進行型多発性硬化症
薬剤クラス別
- 免疫調節
- 免疫抑制剤
- インターフェロン
- その他
診断別
- 血液検査
- 脊髄穿刺
- MRI
- 誘発電位検査
投与経路別
- 注射
- 経口
エンドユーザー別
- 病院
- 専門クリニック
- 在宅ケア
- その他
地域別
- 北米
- 欧州
- アジア太平洋
- 南米
- 中東・アフリカ
市場シェア：企業別（2023年）

第5章世界の多発性硬化症市場の見通し：地域別（2017年～2031年）

北米
- 市場規模と予測
- MSタイプ別
- 薬剤クラス別
- 診断別
- 投与経路別
- エンドユーザー別
- 米国
- カナダ
- メキシコ
欧州
- ドイツ
- フランス
- イタリア
- 英国
- ロシア
- オランダ
- スペイン
- トルコ
- ポーランド
アジア太平洋
- インド
- 中国
- 日本
- オーストラリア
- ベトナム
- 韓国
- インドネシア
- フィリピン
南米
- ブラジル
- アルゼンチン
中東・アフリカ
- サウジアラビア
- アラブ首長国連邦
- 南アフリカ

第6章市場マッピング（2023年）

MSタイプ別
薬剤クラス別
診断別
投与経路別
エンドユーザー別
地域別

第7章マクロ環境と産業構造

需給分析
輸入輸出分析
バリューチェーン分析
PESTEL分析
ポーターのファイブフォース分析

第8章市場力学

成長促進要因
成長抑制要因（課題、抑制要因）

第9章規制枠組みとイノベーション

特許情勢
イノベーション/新技術

第10章主要企業の情勢

マーケットリーダー上位5社の競合マトリクス
マーケットリーダー上位5社の市場収益の分析（2023年）
合併と買収/合弁事業（該当する場合）
SWOT分析（市場企業5社）
特許分析（該当する場合）

第11章価格分析

第12章ケーススタディ

第13章主要企業の見通し

Biogen Inc.
Merck & Co. Inc.
Novartis AG
Pfizer, Inc.
Sanofi SA
Teva Pharmaceutical Industries Ltd
Bristol-Myers Squibb Company
F. Hoffmann-La Roche Ltd
Johnson & Johnson
Mylan NV

第14章戦略的推奨

第15章当社について、免責事項

図表

List of Tables

Table 1. Pricing Analysis of Products from Key Players
Table 2. Competition Matrix of Top 5 Market Leaders
Table 3. Mergers & Acquisitions/ Joint Ventures (If Applicable)
Table 4. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

Figure 1. Global Multiple Sclerosis Market, By Value, In USD Billion, 2017-2031F
Figure 2. Global Multiple Sclerosis Market, By Volume, In Million Units, 2017-2031F
Figure 3. Global Multiple Sclerosis Market Share (%), By Type of MS, 2017-2031F
Figure 4. Global Multiple Sclerosis Market Share (%), By Drug Class, 2017-2031F
Figure 5. Global Multiple Sclerosis Market Share (%), By Diagnosis, 2017-2031F
Figure 6. Global Multiple Sclerosis Market Share (%), By Route of Administration, 2017-2031F
Figure 7. Global Multiple Sclerosis Market Share (%), By End-user, 2017-2031F
Figure 8. Global Multiple Sclerosis Market Share (%), By Region, 2017-2031F
Figure 9. North America Multiple Sclerosis Market, By Value, In USD Billion, 2017-2031F
Figure 10. North America Multiple Sclerosis Market, By Volume, In Million Units, 2017-2031F
Figure 11. North America Multiple Sclerosis Market Share (%), By Type of MS, 2017-2031F
Figure 12. North America Multiple Sclerosis Market Share (%), By Drug Class, 2017-2031F
Figure 13. North America Multiple Sclerosis Market Share (%), By Diagnosis, 2017-2031F
Figure 14. North America Multiple Sclerosis Market Share (%), By Route of Administration, 2017-2031F
Figure 15. North America Multiple Sclerosis Market Share (%), By End-user, 2017-2031F
Figure 16. North America Multiple Sclerosis Market Share (%), By Country, 2017-2031F
Figure 17. United States Multiple Sclerosis Market, By Value, In USD Billion, 2017-2031F
Figure 18. United States Multiple Sclerosis Market, By Volume, In Million Units, 2017-2031F
Figure 19. United States Multiple Sclerosis Market Share (%), By Type of MS, 2017-2031F
Figure 20. United States Multiple Sclerosis Market Share (%), By Drug Class, 2017-2031F
Figure 21. United States Multiple Sclerosis Market Share (%), By Diagnosis, 2017-2031F
Figure 22. United States Multiple Sclerosis Market Share (%), By Route of Administration, 2017-2031F
Figure 23. United States Multiple Sclerosis Market Share (%), By End-user, 2017-2031F
Figure 24. Canada Multiple Sclerosis Market, By Value, In USD Billion, 2017-2031F
Figure 25. Canada Multiple Sclerosis Market, By Volume, In Million Units, 2017-2031F
Figure 26. Canada Multiple Sclerosis Market Share (%), By Type of MS, 2017-2031F
Figure 27. Canada Multiple Sclerosis Market Share (%), By Drug Class, 2017-2031F
Figure 28. Canada Multiple Sclerosis Market Share (%), By Diagnosis, 2017-2031F
Figure 29. Canada Multiple Sclerosis Market Share (%), By Route of Administration, 2017-2031F
Figure 30. Canada Multiple Sclerosis Market Share (%), By End-user, 2017-2031F
Figure 31. Mexico Multiple Sclerosis Market, By Value, In USD Billion, 2017-2031F
Figure 32. Mexico Multiple Sclerosis Market, By Volume, In Million Units, 2017-2031F
Figure 33. Mexico Multiple Sclerosis Market Share (%), By Type of MS, 2017-2031F
Figure 34. Mexico Multiple Sclerosis Market Share (%), By Drug Class, 2017-2031F
Figure 35. Mexico Multiple Sclerosis Market Share (%), By Diagnosis, 2017-2031F
Figure 36. Mexico Multiple Sclerosis Market Share (%), By Route of Administration, 2017-2031F
Figure 37. Mexico Multiple Sclerosis Market Share (%), By End-user, 2017-2031F
Figure 38. Europe Multiple Sclerosis Market, By Value, In USD Billion, 2017-2031F
Figure 39. Europe Multiple Sclerosis Market, By Volume, In Million Units, 2017-2031F
Figure 40. Europe Multiple Sclerosis Market Share (%), By Type of MS, 2017-2031F
Figure 41. Europe Multiple Sclerosis Market Share (%), By Drug Class, 2017-2031F
Figure 42. Europe Multiple Sclerosis Market Share (%), By Diagnosis, 2017-2031F
Figure 43. Europe Multiple Sclerosis Market Share (%), By Route of Administration, 2017-2031F
Figure 44. Europe Multiple Sclerosis Market Share (%), By End-user, 2017-2031F
Figure 45. Europe Multiple Sclerosis Market Share (%), By Country, 2017-2031F
Figure 46. Germany Multiple Sclerosis Market, By Value, In USD Billion, 2017-2031F
Figure 47. Germany Multiple Sclerosis Market, By Volume, In Million Units, 2017-2031F
Figure 48. Germany Multiple Sclerosis Market Share (%), By Type of MS, 2017-2031F
Figure 49. Germany Multiple Sclerosis Market Share (%), By Drug Class, 2017-2031F
Figure 50. Germany Multiple Sclerosis Market Share (%), By Diagnosis, 2017-2031F
Figure 51. Germany Multiple Sclerosis Market Share (%), By Route of Administration, 2017-2031F
Figure 52. Germany Multiple Sclerosis Market Share (%), By End-user, 2017-2031F
Figure 53. France Multiple Sclerosis Market, By Value, In USD Billion, 2017-2031F
Figure 54. France Multiple Sclerosis Market, By Volume, In Million Units, 2017-2031F
Figure 55. France Multiple Sclerosis Market Share (%), By Type of MS, 2017-2031F
Figure 56. France Multiple Sclerosis Market Share (%), By Drug Class, 2017-2031F
Figure 57. France Multiple Sclerosis Market Share (%), By Diagnosis, 2017-2031F
Figure 58. France Multiple Sclerosis Market Share (%), By Route of Administration, 2017-2031F
Figure 59. France Multiple Sclerosis Market Share (%), By End-user, 2017-2031F
Figure 60. Italy Multiple Sclerosis Market, By Value, In USD Billion, 2017-2031F
Figure 61. Italy Multiple Sclerosis Market, By Volume, In Million Units, 2017-2031F
Figure 62. Italy Multiple Sclerosis Market Share (%), By Type of MS, 2017-2031F
Figure 63. Italy Multiple Sclerosis Market Share (%), By Drug Class, 2017-2031F
Figure 64. Italy Multiple Sclerosis Market Share (%), By Diagnosis, 2017-2031F
Figure 65. Italy Multiple Sclerosis Market Share (%), By Route of Administration, 2017-2031F
Figure 66. Italy Multiple Sclerosis Market Share (%), By End-user, 2017-2031F
Figure 67. United Kingdom Multiple Sclerosis Market, By Value, In USD Billion, 2017-2031F
Figure 68. United Kingdom Multiple Sclerosis Market, By Volume, In Million Units, 2017-2031F
Figure 69. United Kingdom Multiple Sclerosis Market Share (%), By Type of MS, 2017-2031F
Figure 70. United Kingdom Multiple Sclerosis Market Share (%), By Drug Class, 2017-2031F
Figure 71. United Kingdom Multiple Sclerosis Market Share (%), By Diagnosis, 2017-2031F
Figure 72. United Kingdom Multiple Sclerosis Market Share (%), By Route of Administration, 2017-2031F
Figure 73. United Kingdom Multiple Sclerosis Market Share (%), By End-user, 2017-2031F
Figure 74. Russia Multiple Sclerosis Market, By Value, In USD Billion, 2017-2031F
Figure 75. Russia Multiple Sclerosis Market, By Volume, In Million Units, 2017-2031F
Figure 76. Russia Multiple Sclerosis Market Share (%), By Type of MS, 2017-2031F
Figure 77. Russia Multiple Sclerosis Market Share (%), By Drug Class, 2017-2031F
Figure 78. Russia Multiple Sclerosis Market Share (%), By Diagnosis, 2017-2031F
Figure 79. Russia Multiple Sclerosis Market Share (%), By Route of Administration, 2017-2031F
Figure 80. Russia Multiple Sclerosis Market Share (%), By End-user, 2017-2031F
Figure 81. Netherlands Multiple Sclerosis Market, By Value, In USD Billion, 2017-2031F
Figure 82. Netherlands Multiple Sclerosis Market, By Volume, In Million Units, 2017-2031F
Figure 83. Netherlands Multiple Sclerosis Market Share (%), By Type of MS, 2017-2031F
Figure 84. Netherlands Multiple Sclerosis Market Share (%), By Drug Class, 2017-2031F
Figure 85. Netherlands Multiple Sclerosis Market Share (%), By Diagnosis, 2017-2031F
Figure 86. Netherlands Multiple Sclerosis Market Share (%), By Route of Administration, 2017-2031F
Figure 87. Netherlands Multiple Sclerosis Market Share (%), By End-user, 2017-2031F
Figure 88. Spain Multiple Sclerosis Market, By Value, In USD Billion, 2017-2031F
Figure 89. Spain Multiple Sclerosis Market, By Volume, In Million Units, 2017-2031F
Figure 90. Spain Multiple Sclerosis Market Share (%), By Type of MS, 2017-2031F
Figure 91. Spain Multiple Sclerosis Market Share (%), By Drug Class, 2017-2031F
Figure 92. Spain Multiple Sclerosis Market Share (%), By Diagnosis, 2017-2031F
Figure 93. Spain Multiple Sclerosis Market Share (%), By Route of Administration, 2017-2031F
Figure 94. Spain Multiple Sclerosis Market Share (%), By End-user, 2017-2031F
Figure 95. Turkey Multiple Sclerosis Market, By Value, In USD Billion, 2017-2031F
Figure 96. Turkey Multiple Sclerosis Market, By Volume, In Million Units, 2017-2031F
Figure 97. Turkey Multiple Sclerosis Market Share (%), By Type of MS, 2017-2031F
Figure 98. Turkey Multiple Sclerosis Market Share (%), By Drug Class, 2017-2031F
Figure 99. Turkey Multiple Sclerosis Market Share (%), By Diagnosis, 2017-2031F
Figure 100. Turkey Multiple Sclerosis Market Share (%), By Route of Administration, 2017-2031F
Figure 101. Turkey Multiple Sclerosis Market Share (%), By End-user, 2017-2031F
Figure 102. Poland Multiple Sclerosis Market, By Value, In USD Billion, 2017-2031F
Figure 103. Poland Multiple Sclerosis Market, By Volume, In Million Units, 2017-2031F
Figure 104. Poland Multiple Sclerosis Market Share (%), By Type of MS, 2017-2031F
Figure 105. Poland Multiple Sclerosis Market Share (%), By Drug Class, 2017-2031F
Figure 106. Poland Multiple Sclerosis Market Share (%), By Diagnosis, 2017-2031F
Figure 107. Poland Multiple Sclerosis Market Share (%), By Route of Administration, 2017-2031F
Figure 108. Poland Multiple Sclerosis Market Share (%), By End-user, 2017-2031F
Figure 109. South America Multiple Sclerosis Market, By Value, In USD Billion, 2017-2031F
Figure 110. South America Multiple Sclerosis Market, By Volume, In Million Units, 2017-2031F
Figure 111. South America Multiple Sclerosis Market Share (%), By Type of MS, 2017-2031F
Figure 112. South America Multiple Sclerosis Market Share (%), By Drug Class, 2017-2031F
Figure 113. South America Multiple Sclerosis Market Share (%), By Diagnosis, 2017-2031F
Figure 114. South America Multiple Sclerosis Market Share (%), By Route of Administration, 2017-2031F
Figure 115. South America Multiple Sclerosis Market Share (%), By End-user, 2017-2031F
Figure 116. South America Multiple Sclerosis Market Share (%), By Country, 2017-2031F
Figure 117. Brazil Multiple Sclerosis Market, By Value, In USD Billion, 2017-2031F
Figure 118. Brazil Multiple Sclerosis Market, By Volume, In Million Units, 2017-2031F
Figure 119. Brazil Multiple Sclerosis Market Share (%), By Type of MS, 2017-2031F
Figure 120. Brazil Multiple Sclerosis Market Share (%), By Drug Class, 2017-2031F
Figure 121. Brazil Multiple Sclerosis Market Share (%), By Diagnosis, 2017-2031F
Figure 122. Brazil Multiple Sclerosis Market Share (%), By Route of Administration, 2017-2031F
Figure 123. Brazil Multiple Sclerosis Market Share (%), By End-user, 2017-2031F
Figure 124. Argentina Multiple Sclerosis Market, By Value, In USD Billion, 2017-2031F
Figure 125. Argentina Multiple Sclerosis Market, By Volume, In Million Units, 2017-2031F
Figure 126. Argentina Multiple Sclerosis Market Share (%), By Type of MS, 2017-2031F
Figure 127. Argentina Multiple Sclerosis Market Share (%), By Drug Class, 2017-2031F
Figure 128. Argentina Multiple Sclerosis Market Share (%), By Diagnosis, 2017-2031F
Figure 129. Argentina Multiple Sclerosis Market Share (%), By Route of Administration, 2017-2031F
Figure 130. Argentina Multiple Sclerosis Market Share (%), By End-user, 2017-2031F
Figure 131. Asia-Pacific Multiple Sclerosis Market, By Value, In USD Billion, 2017-2031F
Figure 132. Asia-Pacific Multiple Sclerosis Market, By Volume, In Million Units, 2017-2031F
Figure 133. Asia-Pacific Multiple Sclerosis Market Share (%), By Type of MS, 2017-2031F
Figure 134. Asia-Pacific Multiple Sclerosis Market Share (%), By Drug Class, 2017-2031F
Figure 135. Asia-Pacific Multiple Sclerosis Market Share (%), By Diagnosis, 2017-2031F
Figure 136. Asia-Pacific Multiple Sclerosis Market Share (%), By Route of Administration, 2017-2031F
Figure 137. Asia- Pacific Multiple Sclerosis Market Share (%), By End-user, 2017-2031F
Figure 138. Asia-Pacific Multiple Sclerosis Market Share (%), By Country, 2017-2031F
Figure 139. India Multiple Sclerosis Market, By Value, In USD Billion, 2017-2031F
Figure 140. India Multiple Sclerosis Market, By Volume, In Million Units, 2017-2031F
Figure 141. India Multiple Sclerosis Market Share (%), By Type of MS, 2017-2031F
Figure 142. India Multiple Sclerosis Market Share (%), By Drug Class, 2017-2031F
Figure 143. India Multiple Sclerosis Market Share (%), By Diagnosis, 2017-2031F
Figure 144. India Multiple Sclerosis Market Share (%), By Route of Administration, 2017-2031F
Figure 145. India Multiple Sclerosis Market Share (%), By End-user, 2017-2031F
Figure 146. China Multiple Sclerosis Market, By Value, In USD Billion, 2017-2031F
Figure 147. China Multiple Sclerosis Market, By Volume, In Million Units, 2017-2031F
Figure 148. China Multiple Sclerosis Market Share (%), By Type of MS, 2017-2031F
Figure 149. China Multiple Sclerosis Market Share (%), By Drug Class, 2017-2031F
Figure 150. China Multiple Sclerosis Market Share (%), By Diagnosis, 2017-2031F
Figure 151. China Multiple Sclerosis Market Share (%), By Route of Administration, 2017-2031F
Figure 152. China Multiple Sclerosis Market Share (%), By End-user, 2017-2031F
Figure 153. Japan Multiple Sclerosis Market, By Value, In USD Billion, 2017-2031F
Figure 154. Japan Multiple Sclerosis Market, By Volume, In Million Units, 2017-2031F
Figure 155. Japan Multiple Sclerosis Market Share (%), By Type of MS, 2017-2031F
Figure 156. Japan Multiple Sclerosis Market Share (%), By Drug Class, 2017-2031F
Figure 157. Japan Multiple Sclerosis Market Share (%), By Diagnosis, 2017-2031F
Figure 158. Japan Multiple Sclerosis Market Share (%), By Route of Administration, 2017-2031F
Figure 159. Japan Multiple Sclerosis Market Share (%), By End-user, 2017-2031F
Figure 160. Australia Multiple Sclerosis Market, By Value, In USD Billion, 2017-2031F
Figure 161. Australia Multiple Sclerosis Market, By Volume, In Million Units, 2017-2031F
Figure 162. Australia Multiple Sclerosis Market Share (%), By Type of MS, 2017-2031F
Figure 163. Australia Multiple Sclerosis Market Share (%), By Drug Class, 2017-2031F
Figure 164. Australia Multiple Sclerosis Market Share (%), By Diagnosis, 2017-2031F
Figure 165. Australia Multiple Sclerosis Market Share (%), By Route of Administration, 2017-2031F
Figure 166. Australia Multiple Sclerosis Market Share (%), By End-user, 2017-2031F
Figure 167. Vietnam Multiple Sclerosis Market, By Value, In USD Billion, 2017-2031F
Figure 168. Vietnam Multiple Sclerosis Market, By Volume, In Million Units, 2017-2031F
Figure 169. Vietnam Multiple Sclerosis Market Share (%), By Type of MS, 2017-2031F
Figure 170. Vietnam Multiple Sclerosis Market Share (%), By Drug Class, 2017-2031F
Figure 171. Vietnam Multiple Sclerosis Market Share (%), By Diagnosis, 2017-2031F
Figure 172. Vietnam Multiple Sclerosis Market Share (%), By Route of Administration, 2017-2031F
Figure 173. Vietnam Multiple Sclerosis Market Share (%), By End-user, 2017-2031F
Figure 174. South Korea Multiple Sclerosis Market, By Value, In USD Billion, 2017-2031F
Figure 175. South Korea Multiple Sclerosis Market, By Volume, In Million Units, 2017-2031F
Figure 176. South Korea Multiple Sclerosis Market Share (%), By Type of MS, 2017-2031F
Figure 177. South Korea Multiple Sclerosis Market Share (%), By Drug Class, 2017-2031F
Figure 178. South Korea Multiple Sclerosis Market Share (%), By Diagnosis, 2017-2031F
Figure 179. South Korea Multiple Sclerosis Market Share (%), By Route of Administration, 2017-2031F
Figure 180. South Korea Multiple Sclerosis Market Share (%), By End-user, 2017-2031F
Figure 181. Indonesia Multiple Sclerosis Market, By Value, In USD Billion, 2017-2031F
Figure 182. Indonesia Multiple Sclerosis Market, By Volume, In Million Units, 2017-2031F
Figure 183. Indonesia Multiple Sclerosis Market Share (%), By Type of MS, 2017-2031F
Figure 184. Indonesia Multiple Sclerosis Market Share (%), By Drug Class, 2017-2031F
Figure 185. Indonesia Multiple Sclerosis Market Share (%), By Diagnosis, 2017-2031F
Figure 186. Indonesia Multiple Sclerosis Market Share (%), By Route of Administration, 2017-2031F
Figure 187. Indonesia Multiple Sclerosis Market Share (%), By End-user, 2017-2031F
Figure 188. Philippines Multiple Sclerosis Market, By Value, In USD Billion, 2017-2031F
Figure 189. Philippines Multiple Sclerosis Market, By Volume, In Million Units, 2017-2031F
Figure 190. Philippines Multiple Sclerosis Market Share (%), By Type of MS, 2017-2031F
Figure 191. Philippines Multiple Sclerosis Market Share (%), By Drug Class, 2017-2031F
Figure 192. Philippines Multiple Sclerosis Market Share (%), By Diagnosis, 2017-2031F
Figure 193. Philippines Multiple Sclerosis Market Share (%), By Route of Administration, 2017-2031F
Figure 194. Philippines Multiple Sclerosis Market Share (%), By End-user, 2017-2031F
Figure 195. Middle East & Africa Multiple Sclerosis Market, By Value, In USD Billion, 2017-2031F
Figure 196. Middle East & Africa Multiple Sclerosis Market, By Volume, In Million Units, 2017-2031F
Figure 197. Middle East & Africa Multiple Sclerosis Market Share (%), By Type of MS, 2017-2031F
Figure 198. Middle East & Africa Multiple Sclerosis Market Share (%), By Drug Class, 2017-2031F
Figure 199. Middle East & Africa Multiple Sclerosis Market Share (%), By Diagnosis, 2017-2031F
Figure 200. Middle East & Africa Multiple Sclerosis Market Share (%), By Route of Administration, 2017-2031F
Figure 201. Middle East & Africa Multiple Sclerosis Market Share (%), By End-user, 2017-2031F
Figure 202. Middle East & Africa Multiple Sclerosis Market Share (%), By Country, 2017-2031F
Figure 203. Saudi Arabia Multiple Sclerosis Market, By Value, In USD Billion, 2017-2031F
Figure 204. Saudi Arabia Multiple Sclerosis Market, By Volume, In Million Units, 2017-2031F
Figure 205. Saudi Arabia Multiple Sclerosis Market Share (%), By Type of MS, 2017-2031F
Figure 206. Saudi Arabia Multiple Sclerosis Market Share (%), By Drug Class, 2017-2031F
Figure 207. Saudi Arabia Multiple Sclerosis Market Share (%), By Diagnosis, 2017-2031F
Figure 208. Saudi Arabia Multiple Sclerosis Market Share (%), By Route of Administration, 2017-2031F
Figure 209. Saudi Arabia Multiple Sclerosis Market Share (%), By End-user, 2017-2031F
Figure 210. UAE Multiple Sclerosis Market, By Value, In USD Billion, 2017-2031F
Figure 211. UAE Multiple Sclerosis Market, By Volume, In Million Units, 2017-2031F
Figure 212. UAE Multiple Sclerosis Market Share (%), By Type of MS, 2017-2031F
Figure 213. UAE Multiple Sclerosis Market Share (%), By Drug Class, 2017-2031F
Figure 214. UAE Multiple Sclerosis Market Share (%), By Diagnosis, 2017-2031F
Figure 215. UAE Multiple Sclerosis Market Share (%), By Route of Administration, 2017-2031F
Figure 216. UAE Multiple Sclerosis Market Share (%), By End-user, 2017-2031F
Figure 217. South Africa Multiple Sclerosis Market, By Value, In USD Billion, 2017-2031F
Figure 218. South Africa Multiple Sclerosis Market, By Volume, In Million Units, 2017-2031F
Figure 219. South Africa Multiple Sclerosis Market Share (%), By Type of MS, 2017-2031F
Figure 220. South Africa Multiple Sclerosis Market Share (%), By Drug Class, 2017-2031F
Figure 221. South Africa Multiple Sclerosis Market Share (%), By Diagnosis, 2017-2031F
Figure 222. South Africa Multiple Sclerosis Market Share (%), By Route of Administration, 2017-2031F
Figure 223. South Africa Multiple Sclerosis Market Share (%), By End-user, 2017-2031F
Figure 224. By Type of MS Map-Market Size (USD Billion) & Growth Rate (%), 2023
Figure 225. By Drug Class Map-Market Size (USD Billion) & Growth Rate (%), 2023
Figure 226. By Diagnosis Map-Market Size (USD Billion) & Growth Rate (%), 2023
Figure 227. By Route of Administration Map-Market Size (USD Billion) & Growth Rate (%), 2023
Figure 228. By End-user Map-Market Size (USD Billion) & Growth Rate (%), 2023
Figure 229. By Region Map-Market Size (USD Billion) & Growth Rate (%), 2023

Product Code: MX11505

Global multiple sclerosis market is projected to witness a CAGR of 4.24% during the forecast period 2024-2031, growing from USD 27.12 billion in 2023 to USD 37.81 billion in 2031. Various factors are shaping the global multiple sclerosis market, such as initiatives undertaken by the governments of different countries, technological advancements, increasing demand for immunosuppressant drugs, treatment of relapsing-remitting disease, and growing focus on research and development.

Governments across the world have been taking numerous initiatives to guide and educate people about the treatments used to manage multiple sclerosis and to promote public awareness of the disease. These initiatives help to speed up the expansion of the global multiple sclerosis market and support regional development. Tools based on artificial intelligence are increasingly being used and have disrupted the global multiple sclerosis market. These tools have transformed the global multiple sclerosis market by leading to changes in the development of novel medicines. There has been an increase in the research capacity, leading to the development of more advanced and precise drugs for treating multiple sclerosis.

The growth of global multiple sclerosis market is being influenced by the rising demand for immunosuppressant drugs for treating different types of multiple sclerosis. These medications alter the immune system's response and are responsible for reducing inflammation and slowing down the aging process. The global multiple sclerosis market is being driven by the increasing demand for the drugs available to treat relapsing-remitting multiple sclerosis. Various companies focus on developing customized treatments to fulfill the demand by addressing specific difficulties and symptoms associated with the disease. Key players in the global multiple sclerosis market prioritize improving the disease's progression by focusing on improving symptomatic management through research and development. These initiatives are bolstering the development of innovative technologies for disease management.

For instance, in May 2024, Alexander Gow, Ph.D., professor and associate director of the Center for Molecular Medicine and Genetics, as well as professor of pediatrics and neurology at Wayne State University School of Medicine, was granted USD 644,827 for three years by the NMSS (National Multiple Sclerosis Society) to find the possible causes of multiple sclerosis.

Government Initiatives to Drive the Market Growth

Lately, the global multiple sclerosis market has been observing growth due to the active involvement of governments across the world. Governments are proactively taking several steps to promote the development of the market, such as boosting research and development in the industry, spreading awareness about multiple sclerosis, and organizing various educational programs. Through these initiatives, the government wants to increase awareness about the disease and make innovative treatments accessible to patients while improving the healthcare system's infrastructure. Such initiatives aid in propelling market growth and are essential in meeting the patient's unmet needs while promoting innovative solutions for better disease management.

For instance, MS Australia, a prominent national non-profit organization, applauded the government's commitment to fund health and medical research in May 2024 but expressed concern that neurological research is not receiving enough funding or attention. The organization called for the creation of a Neurological Research Mission stated that neurological disorders such as multiple sclerosis (MS) should be a key national priority for medical research.

Technological Advancements to Facilitate the Market

The use of artificial intelligence is facilitating the development of more advanced and efficient treatments for multiple sclerosis, thus being a major factor driving the growth of the global multiple sclerosis market. These advanced instruments support the development of disease-specific medications that help create customized treatment plans that meet the requirements of every patient. AI can be highly useful in analyzing radiological images, such as magnetic resonance imaging (MRI) scans, which are essential in diagnosing multiple sclerosis.

For instance, in May 2024, Head Diagnostics (Dublin, Ireland) and the Royal College of Surgeons in Ireland collaborated on clinical research to improve the monitoring and assessment of Multiple Sclerosis (MS) using cutting-edge technologies. The study, which was started in conjunction with World MS Day, aims to provide more impartiality in the evaluation of the condition by investigating the application of novel digital biomarkers to monitor disease.

Increasing Demand for Immunosuppressant Drugs

Immunosuppressant drugs are excessively used globally as they tend to protect the myelin sheath from the harmful effects of the overactive immune system. These drugs suppress the immune system's reaction and reduce inflammation in the myelin sheath. Immunosuppressant drugs provide adequate results against the disease by prolonging the course of the disease. There has been a significant rise in demand for these drugs in the global multiple sclerosis market due to the rapid rise in the prevalence of the disease.

In February 2024, Roche Pharma introduced Ocrelizumab, sold under the brand name Ocrevus, in the Indian market for the management of multiple sclerosis and the slow progression of disability. Ocrevus is an immunosuppressant drug made from artificially produced antibodies obtained from human cells.

Treatment of Relapsing-Remitting MS

The increase in demand for drugs used to treat relapsing-remitting multiple sclerosis is a major factor driving the growth of the global multiple sclerosis market. Recently, several major companies have been making efforts to increase the efficiency of the drugs used to treat relapsing-remitting multiple sclerosis through improvements in drug research. Alternative treatment options are available to the patients through immunomodulators and immunosuppressants. These alternatives are highly efficient in treating disease as they can address the personalized requirements of patients. Pharmaceutical companies are expected to diverge their products related to RRMS (relapsing-remitting multiple sclerosis) due to the growing number of cases.

For instance, the U.S. Patent and Trademark Office (USPTO) granted a new patent covering the use of Ponvory (ponesimod), an oral medication approved for treating relapsing forms of multiple sclerosis (MS), spanning nearly two decades, according to a January 2024 announcement from Vanda Pharmaceuticals, a well-known international biopharmaceutical company. The recently granted patent particularly covers techniques for lowering clinical management events both before and during Ponvory treatment, as well as strategies for resuming medication following missing doses.

European Markets are Growing at a Fast Pace

Europe's multiple sclerosis market has observed significant changes. Companies focus on manufacturing new products through research and development, raising public knowledge of multiple sclerosis and its therapies. The global multiple sclerosis market participants focus on continuous clinical trials to improve the efficacy of the medications. The market is expanding due to pharmaceutical companies and concerned authorities meeting patient requirements, surpassing challenges such as diagnosis limitations.

For instance, in February 2024, Neuraxpharm Group, a European specialty pharmaceutical company focused on treating CNS disorders, announced the launch of BRIUMVI (ublituximab) in Europe. In adult patients, BRIUMVI is used for the treatment of relapsing multiple sclerosis with active disease. The drug was first launched in Germany and then in the rest of Europe.

Future Market Scenario (2024 - 2031F)

Cost-effective solutions such as biosimilars will reshape treatment options in the global multiple sclerosis market.

Advancements and growing demand for precision medicine will drive the need for personalized treatment options in the global multiple sclerosis market.

The integration of digital health solutions, such as telemedicine and remote monitoring, will influence the global multiple sclerosis market.

Increase in innovations in regenerative therapies offer promise for the treatment, boosting the growth of the global multiple sclerosis market.

Key Players Landscape and Outlook

Collaborations and partnerships have played an integral role in the growth of the global multiple sclerosis market. These collaborations ensure that different perspectives are considered to fulfill the diverse nature of the requirements. Pharmaceutical firms, healthcare providers, and government organizations are the major stakeholders in the market. The wide representation guarantees that different viewpoints are considered, resulting in more thorough and efficient solutions. Patient participation and engagement in the research process are prioritized in many collaborations. The method guarantees that therapies are customized to address the unique requirements and worries of individuals suffering from multiple sclerosis.

To operate and develop digital health solutions for rare diseases and neurological diseases such as multiple sclerosis, Aptar Digital Health, a division of AptarGroup, Inc., a global leader in drug and consumer product dosing, dispensing, and protection technologies, entered into an enterprise agreement with Biogen Inc. in February 2024. Under the terms of the transaction, Biogen gave Aptar Digital Health (Aptar) ownership of several digital health products.

1. Research Methodology

2. Project Scope and Definitions

3. Executive Summary

4. Global Multiple Sclerosis Market Outlook, 2017-2031F

4.1. Market Size & Forecast
- 4.1.1. By Value
- 4.1.2. By Volume
4.2. By Type of MS
- 4.2.1. Clinically Isolated Syndrome
- 4.2.2. Relapsing-remitting MS
- 4.2.3. Secondary Progressive MS
- 4.2.4. Primary Progressive MS
4.3. By Drug Class
- 4.3.1. Immunomodulatory
- 4.3.2. Immunosuppressant
- 4.3.3. Interferon
- 4.3.4. Others
4.4. By Diagnosis
- 4.4.1. Blood Tests
- 4.4.2. Spinal tap
- 4.4.3. MRI
- 4.4.4. Evoked Potential Tests
4.5. By Route of Administration
- 4.5.1. Injectable
- 4.5.2. Oral
4.6. By End-user
- 4.6.1. Hospitals
- 4.6.2. Specialty Clinics
- 4.6.3. Homecare
- 4.6.4. Others
4.7. By Region
- 4.7.1. North America
- 4.7.2. Europe
- 4.7.3. Asia-Pacific
- 4.7.4. South America
- 4.7.5. Middle East and Africa
4.8. By Company Market Share (%), 2023

5. Global Multiple Sclerosis Market Outlook, By Region, 2017-2031F

5.1. North America*
- 5.1.1. Market Size & Forecast
  - 5.1.1.1. By Value
  - 5.1.1.2. By Volume
- 5.1.2. By Type of MS
  - 5.1.2.1. Clinically Isolated Syndrome
  - 5.1.2.2. Relapsing-remitting MS
  - 5.1.2.3. Secondary Progressive MS
  - 5.1.2.4. Primary Progressive MS
- 5.1.3. By Drug Class
  - 5.1.3.1. Immunomodulatory
  - 5.1.3.2. Immunosuppressant
  - 5.1.3.3. Interferon
  - 5.1.3.4. Others
- 5.1.4. By Diagnosis
  - 5.1.4.1. Blood Tests
  - 5.1.4.2. Spinal tap
  - 5.1.4.3. MRI
  - 5.1.4.4. Evoked Potential Tests
- 5.1.5. By Route of Administration
  - 5.1.5.1. Injectable
  - 5.1.5.2. Oral
- 5.1.6. By End-user
  - 5.1.6.1. Hospitals
  - 5.1.6.2. Specialty Clinics
  - 5.1.6.3. Homecare
  - 5.1.6.4. Others
- 5.1.7. United States*
  - 5.1.7.1. Market Size & Forecast
    - 5.1.7.1.1. By Value
    - 5.1.7.1.2. By Volume
  - 5.1.7.2. By Type of MS
    - 5.1.7.2.1. Clinically Isolated Syndrome
    - 5.1.7.2.2. Relapsing-remitting MS
    - 5.1.7.2.3. Secondary Progressive MS
    - 5.1.7.2.4. Primary Progressive MS
  - 5.1.7.3. By Drug Class
    - 5.1.7.3.1. Immunomodulatory
    - 5.1.7.3.2. Immunosuppressant
    - 5.1.7.3.3. Interferon
    - 5.1.7.3.4. Others
  - 5.1.7.4. By Diagnosis
    - 5.1.7.4.1. Blood Tests
    - 5.1.7.4.2. Spinal tap
    - 5.1.7.4.3. MRI
    - 5.1.7.4.4. Evoked Potential Tests
  - 5.1.7.5. By Route of Administration
    - 5.1.7.5.1. Injectable
    - 5.1.7.5.2. Oral
  - 5.1.7.6. By End-user
    - 5.1.7.6.1. Hospitals
    - 5.1.7.6.2. Specialty Clinics
    - 5.1.7.6.3. Homecare
    - 5.1.7.6.4. Others
- 5.1.8. Canada
- 5.1.9. Mexico

All segments will be provided for all regions and countries covered

5.2. Europe
- 5.2.1. Germany
- 5.2.2. France
- 5.2.3. Italy
- 5.2.4. United Kingdom
- 5.2.5. Russia
- 5.2.6. Netherlands
- 5.2.7. Spain
- 5.2.8. Turkey
- 5.2.9. Poland
5.3. Asia-Pacific
- 5.3.1. India
- 5.3.2. China
- 5.3.3. Japan
- 5.3.4. Australia
- 5.3.5. Vietnam
- 5.3.6. South Korea
- 5.3.7. Indonesia
- 5.3.8. Philippines
5.4. South America
- 5.4.1. Brazil
- 5.4.2. Argentina
5.5. Middle East and Africa
- 5.5.1. Saudi Arabia
- 5.5.2. UAE
- 5.5.3. South Africa

6. Market Mapping, 2023

6.1. By Type of MS
6.2. By Drug Class
6.3. By Diagnosis
6.4. By Route of Administration
6.5. By End-user
6.6. By Region

7. Macro Environment and Industry Structure

7.1. Demand Supply Analysis
7.2. Import Export Analysis
7.3. Value Chain Analysis
7.4. PESTEL Analysis
- 7.4.1. Political Factors
- 7.4.2. Economic System
- 7.4.3. Social Implications
- 7.4.4. Technological Advancements
- 7.4.5. Environmental Impacts
- 7.4.6. Legal Compliances and Regulatory Policies (Statutory Bodies Included)
7.5. Porter's Five Forces Analysis
- 7.5.1. Supplier Power
- 7.5.2. Buyer Power
- 7.5.3. Substitution Threat
- 7.5.4. Threat from New Entrant
- 7.5.5. Competitive Rivalry

8. Market Dynamics

8.1. Growth Drivers
8.2. Growth Inhibitors (Challenges and Restraints)

9. Regulatory Framework and Innovation

9.1. Patent Landscape
9.2. Innovations/Emerging Technologies

10. Key Players Landscape

10.1. Competition Matrix of Top Five Market Leaders
10.2. Market Revenue Analysis of Top Five Market Leaders (By Value, 2023)
10.3. Mergers and Acquisitions/Joint Ventures (If Applicable)
10.4. SWOT Analysis (For Five Market Players)
10.5. Patent Analysis (If Applicable)

11. Pricing Analysis

12. Case Studies

13. Key Players Outlook

13.1. Biogen Inc.
- 13.1.1. Company Details
- 13.1.2. Key Management Personnel
- 13.1.3. Products and Services
- 13.1.4. Financials (As reported)
- 13.1.5. Key Market Focus and Geographical Presence
- 13.1.6. Recent Developments
13.2. Merck & Co. Inc.
13.3. Novartis AG
13.4. Pfizer, Inc.
13.5. Sanofi SA
13.6. Teva Pharmaceutical Industries Ltd
13.7. Bristol-Myers Squibb Company
13.8. F. Hoffmann-La Roche Ltd
13.9. Johnson & Johnson
13.10. Mylan NV

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

多発性硬化症の世界市場の評価：MSタイプ別、薬剤クラス別、診断別、投与経路別、エンドユーザー別、地域別、機会、予測（2017年～2031年）

Multiple Sclerosis Market Assessment, By Type of MS, By Drug Class, By Diagnosis, By Route of Administration, By End-user, By Region, Opportunities and Forecast, 2017-2031F

全表示

目次

第1章調査手法

第2章プロジェクトの範囲と定義

第3章エグゼクティブサマリー

第4章世界の多発性硬化症市場の見通し（2017年～2031年）

第5章世界の多発性硬化症市場の見通し：地域別（2017年～2031年）

第6章市場マッピング（2023年）

第7章マクロ環境と産業構造

第8章市場力学

第9章規制枠組みとイノベーション

第10章主要企業の情勢

第11章価格分析

第12章ケーススタディ

第13章主要企業の見通し

第14章戦略的推奨

第15章当社について、免責事項

List of Tables

List of Figures

Table of Contents

1. Research Methodology

2. Project Scope and Definitions

3. Executive Summary

4. Global Multiple Sclerosis Market Outlook, 2017-2031F

5. Global Multiple Sclerosis Market Outlook, By Region, 2017-2031F

6. Market Mapping, 2023

7. Macro Environment and Industry Structure

8. Market Dynamics

9. Regulatory Framework and Innovation

10. Key Players Landscape

11. Pricing Analysis

12. Case Studies

13. Key Players Outlook

14. Strategic Recommendations

15. About Us and Disclaimer

多発性硬化症の世界市場の評価：MSタイプ別、薬剤クラス別、診断別、投与経路別、エンドユーザー別、地域別、機会、予測（2017年～2031年）

Multiple Sclerosis Market Assessment, By Type of MS, By Drug Class, By Diagnosis, By Route of Administration, By End-user, By Region, Opportunities and Forecast, 2017-2031F

全表示

目次

第1章 調査手法

第2章 プロジェクトの範囲と定義

第3章 エグゼクティブサマリー

第4章 世界の多発性硬化症市場の見通し（2017年～2031年）

第5章 世界の多発性硬化症市場の見通し：地域別（2017年～2031年）

第6章 市場マッピング（2023年）

第7章 マクロ環境と産業構造

第8章 市場力学

第9章 規制枠組みとイノベーション

第10章 主要企業の情勢

第11章 価格分析

第12章 ケーススタディ

第13章 主要企業の見通し

第14章 戦略的推奨

第15章 当社について、免責事項

List of Tables

List of Figures

Table of Contents

1. Research Methodology

2. Project Scope and Definitions

3. Executive Summary

4. Global Multiple Sclerosis Market Outlook, 2017-2031F

5. Global Multiple Sclerosis Market Outlook, By Region, 2017-2031F

6. Market Mapping, 2023

7. Macro Environment and Industry Structure

8. Market Dynamics

9. Regulatory Framework and Innovation

10. Key Players Landscape

11. Pricing Analysis

12. Case Studies

13. Key Players Outlook

14. Strategic Recommendations

15. About Us and Disclaimer

第1章調査手法

第2章プロジェクトの範囲と定義

第3章エグゼクティブサマリー

第4章世界の多発性硬化症市場の見通し（2017年～2031年）

第5章世界の多発性硬化症市場の見通し：地域別（2017年～2031年）

第6章市場マッピング（2023年）

第7章マクロ環境と産業構造

第8章市場力学

第9章規制枠組みとイノベーション

第10章主要企業の情勢

第11章価格分析

第12章ケーススタディ

第13章主要企業の見通し

第14章戦略的推奨

第15章当社について、免責事項